Live Breaking News & Updates on Drug licensing authorities

Stay informed with the latest breaking news from Drug licensing authorities on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Drug licensing authorities and stay connected to the pulse of your community

SC widens its ambit on Patanajali misleading ads, blames IMA, others on misguiding public | Central India's Premier English Daily

New Delhi, Apr 23 (UNI) Supreme Court on Tuesday took note that Patanjali's Founder Baba Ramdev has issued public apology in 67 Newspapers after its last order. A bench comprising Justice Hima Kohli and Justice Ahsanuddin Amanullah asked Ramdev to file a proper affidavit in this regard. The apex court remarked on the tiny size

New-delhi , Delhi , India , Acharya-balkrishna , Baba-ramdev , Justice-ahsanuddin-amanullah , Supreme-court , Affairs-ministries , Supreme-court-on , Indian-medical-association-doctors , Top-court , Medicines-health

DRDO's 2DG found effective against all variants of COVID-19: Study

DRDO's 2DG found effective against all variants of COVID-19: Study
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.

Institute-of-nuclear-medicine , Nuclear-medicine , Allied-sciences , Active-pharmaceutical-ingredient , Drug-licensing-authorities , நிறுவனம்-ஆஃப்-அணு-மருந்து , அணு-மருந்து , கூட்டணி-அறிவியல் , செயலில்-மருந்து-மூலப்பொருள் ,

DRDO Invites Applications From Indian Pharma Firms For Bulk Production Of COVID-19 Drug 2-DG

The Defence Research and Development Organisation or DRDO, which developed 2-Deoxy-D-Glucose (2-DG), a drug used for treatment of COVID-19 patients, has called for Expression of Interest to transfer the technology to Indian pharmaceutical firms.

Indian-pharma , Technical-assessment-committee , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , First-come-served-basis , Active-pharmaceutical-ingredient , Drug-licensing-authorities , Covid-19-drug-2-dg , Drdo-covid-drug-2-dg

drdo 2dg drug: DRDO invites EoI to transfer technology of 2-DG drug for bulk production

According to the EoI document, applications should be submitted before June 17 through email. "The EoI submitted by industries will be scrutinised by a Technical Assessment Committee (TAC). Only up to 15 industries will be given ToT on their capabilities, technical hand holding capability of DRDO and on First Come First Served Basis," it said.

Technical-assessment-committee , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , First-come-served-basis , Active-pharmaceutical-ingredient , Drug-licensing-authorities , Drdo-2dg-drug , Inmas

DRDO To Transfer Technology Of Anti-COVID Drug '2-DG' To India Pharma Firms, Invites EoI

DRDO To Transfer Technology Of Anti-COVID Drug '2-DG' To India Pharma Firms, Invites EoI
by Swarajya Staff - Jun 9, 2021 07:25 AM
DRDO Logo (Pic Via Wikipedia)
The Defence Research and Development Organisation (DRDO) has sought Expression of Interest (EoI) for transfer of technology for bulk manufacturing of the 2-Deoxy-D-Glucose (2-DG), a drug developed by the DRDO for treatment of Covid-19 patients.
The drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of the DRDO, in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad.
2-DG is a glucose analogue, which has the 2-hydroxyl group replaced by hydrogen. The molecule is transported in cells by the glucose transporters on the cell membrane but it cannot undergo further glycolysis and act as inhibitor of glycolysis. Therefore, cells with higher glucose uptake, for example tumor cells, virally infected cells, inflammatory cells have also a higher uptake of 2-DG.

Hyderabad , Andhra-pradesh , India , Technical-assessment-committee , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , Drug-controller-general , Come-first-served

DRDO invites EoI to transfer technology of 2-DG drug for bulk production

The 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr. Reddy’s Laboratories.

Technical-assessment-committee , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , Active-pharmaceutical-ingredient , Drug-licensing-authorities , Defence-research-and-development-organisation , Drdo , 2-dg

DRDO invites EoI to transfer technology of COVID 2-DG drug for bulk production

According to the EoI document, applications should be submitted before June 17 through email

Hyderabad , Andhra-pradesh , India , Technical-assessment-committee , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , First-come-served-basis , Active-pharmaceutical-ingredient

Covid treatment: DRDO invites bids to transfer technology of 2-DG drug

Requirements for the bidders include a drug license to manufacture Active Pharmaceutical Ingredient (API) from Drug Licensing Authorities and WHO GMP (Good Manufacturing Practices) certification

Active-pharmaceutical-ingredient , Drug-licensing-authorities , Good-manufacturing-practices , 2dg-production , 2-dg-production , 2dg-availability , 2-dg , Covid-treatment-drug , Covid-treatment-news , Covid-treatment-list , Covid-treatment

DRDO invites EoI to transfer technology of 2-DG drug for bulk production | India News

India News: The Defence Research and Development Organisation (DRDO), which developed 2-Deoxy-D- Glucose (2-DG), a drug used for treatment of Covid-19 patients,

Hyderabad , Andhra-pradesh , India , Technical-assessment-committee , Institute-of-nuclear-medicine , Development-organisation , Defence-research , Nuclear-medicine , Allied-sciences , First-come-served-basis , Active-pharmaceutical-ingredient